Dogwood Therapeutics (DWTX) Enterprise Value (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Enterprise Value of -$13.2 million for Q1 2026, up 24.58% year-over-year from -$10.6 million in Q1 2025, and down 102.73% quarter-over-quarter from -$6.5 million in Q4 2025.
Dogwood Therapeutics (DWTX) Enterprise Value (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Enterprise Value for 7 consecutive years, with -$13.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 24.58% year-over-year to -$13.2 million; the TTM figure through Mar 2026 stood at -$13.2 million (up 24.58% YoY), while the FY2025 annual figure was -$6.5 million, up 56.06% from the prior year.
- Enterprise Value slipped to -$13.2 million in Q1 2026 per DWTX's latest filing, from -$6.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$2.0 million in Q3 2024 and bottomed at -$17.5 million in Q1 2025.
- Historically, Enterprise Value has averaged -$8.1 million across 5 years, with a median of -$7.0 million in 2022.
- Annual changes were most pronounced in 2022 — Enterprise Value surged 64.76% — and 2025, when it tumbled 637.08%.
- Dogwood Therapeutics' Enterprise Value stood at -$7.0 million in 2022, then soared by 52.82% to -$3.3 million in 2023, then sank by 347.64% to -$14.8 million in 2024, then soared by 56.06% to -$6.5 million in 2025, then tumbled by 102.73% to -$13.2 million in 2026.
- Business Quant data shows DWTX's Enterprise Value at -$13.2 million in Q1 2026, -$6.5 million in Q4 2025, and -$10.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | -9.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.23 Mn |
| Dec 31, 2025 | -6.52 Mn |
| Sep 30, 2025 | -10.13 Mn |
| Jun 30, 2025 | -13.40 Mn |
| Mar 31, 2025 | -17.54 Mn |
| Dec 31, 2024 | -14.85 Mn |
| Sep 30, 2024 | -2.04 Mn |
| Jun 30, 2024 | -3.02 Mn |
| Mar 31, 2024 | -2.38 Mn |
| Dec 31, 2023 | -3.32 Mn |
| Sep 30, 2023 | -4.79 Mn |
| Jun 30, 2023 | -4.59 Mn |
| Mar 31, 2023 | -5.33 Mn |
| Dec 31, 2022 | -7.03 Mn |
| Sep 30, 2022 | -9.79 Mn |
| Jun 30, 2022 | -7.70 Mn |
| Mar 31, 2022 | -11.35 Mn |
| Dec 31, 2021 | -14.01 Mn |
| Sep 30, 2021 | -19.19 Mn |
| Jun 30, 2021 | -21.84 Mn |